NCT-58
/ Korea University, Seoul National University
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 09, 2022
A novel C-terminal HSP90 inhibitor NCT-58 targets cancer stem-like properties and suppresses migratory ability in triple-negative breast cancer cells
(AACR 2022)
- "These findings suggest that NCT-58 may represent an effective therapeutic approach for the simultaneous targeting of HSP90 and its client oncoproteins for the treatment of molecularly heterogeneous TNBC."
Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ALDH1A1 • CD24 • CD44 • STAT3 • VIM
1 to 1
Of
1
Go to page
1